ProteoNic Announces Extension of GigaGen’s Rights to 2G UNic™ Technology

SUFFER, Netherlands, November 1, 2022 /PRNewswire/ — ProteoNic BV, a leading provider of premium vector technology and services for the efficient production of biologics, today announced the renewal of its license agreement with GigaGen, a biotechnology company developing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistance and cancer and a subsidiary of Grifols.

Under the terms of the agreement, GigaGen will receive non-exclusive, worldwide commercial rights to use ProteoNic’s technology platform for the development and manufacturing of its mono- and polyclonal antibody drug candidates. Financial terms of the agreement were not disclosed.

ProteoNic’s protein expression technology, 2G UNic™, improves production levels of recombinant proteins in a range of mammalian host cells, selection systems and protein targets. This is achieved through the combined action of novel genetic elements that together exert a positive effect on recombinant protein production levels. The technology increases production levels of complex proteins that are difficult to produce, including bispecific and fusion molecules, and product levels that are already in the several g/L range. In addition, 2G UNic™ can be used to boost the performance of other expression-enhancing technologies.

Carter KellerGrifols Senior Vice President and Head of GigaGen commented, “The deployment of ProteoNic’s technology has had a significant impact on the production levels of our poly- and monoclonal antibody drugs. This expanded license agreement allows us to develop our product candidates with higher yields and improvements in overall cost and efficiencies of manufacture.”

Frank PieperCEO of ProteoNic, added, “We are pleased to contribute to the successful development and manufacturing of GigaGen’s recombinant antibody drugs by providing broad access to our technology.”

About ProteoNic

ProteoNic is a private company with offices in Leiden, the Netherlands and in the Boston Area, United States of America. The Company provides technology and services for the generation of cell lines with greatly improved biologics production properties, including production levels and stability. The company commercializes its proprietary 2G UNic™ technology through licensing and partnership agreements. Visit www.proteonic.nl for more information.

About gigagen inc

GigaGen is developing transformative antibody drugs for immunodeficiency, infectious diseases and checkpoint-resistant cancers using industry-leading single-cell technologies. Its novel technology platforms uniquely capture and reconstruct entire immune repertoires as functional antibody libraries. This approach has enabled the development of first-in-class recombinant polyclonal antibody therapies to treat infectious diseases. In addition, GigaGen’s lead oncology compound, GIGA-564, is an anti-CTLA-4 monoclonal antibody that has demonstrated enhanced anti-tumor efficacy in vivo through a unique mechanism of action. Visit www.grifols.com or www.gigagen.com for more information.

For more information, please contact:

proteonic
Markus PosnoPh.D
Vice President Business Development
T: +1 617 480 8016
E: [email protected]

Logo: https://mma.prnewswire.com/media/1804728/ProteoNic_Logo.jpg

SOURCE ProteoNic

source

Leave a Reply

Your email address will not be published. Required fields are marked *